新风胶囊对强直性脊柱炎的疗效及生活质量的影响

Therapeutic Effects of Xinfeng Capsules in Treatment of Ankylosing Spondylitis and Its Effects on Quality of Life

目的观察新风胶囊(Xinfeng Capsules,XFC)治疗强直性脊柱炎(ankylosing spondylitis,AS)的临床疗效及其对生活质量的影响,探讨其作用机制。方法将60例AS患者按随机数字表分成2组,治疗组(40例)和对照组(20例)分别采用XFC、柳氮磺胺吡啶治疗。治疗前后分别观察两组的主要症状体征积分和生活质量评分的变化,及血浆急性时相反应物血沉(erythrosedimentation,ESR)和C-反应蛋白(C-reactive protein,CRP)水平的变化,并对Bath强直性脊柱炎计量学指数(Bath ankylosing spondylitis metrologi-cal index,BASMI)、Bath强直性脊柱炎功能指数(Bath ankylosing spondylitis functional index,BASFI)、Bath强直性脊柱炎疾病活动指数(Bath ankylosing spondylitis activity index,BASDAI)、Bath强直性脊柱炎整体指数(Bath ankylosing spondylitis global index,BAS-G)进行评定,生活质量测评采用WHO生活质量简表(brief version of WHO quality of life,WHOQOL-BRIEF),疼痛程度测评采用视觉模拟评分法(vis-ual analog scoring,VAS),焦虑和抑郁状态测评采用焦虑自评量表(self-rating anxiety scores,SAS)和抑郁自评量表(self-rating depression scores,SDS),临床疗效评价采用国际AS评估(assessment in ankylosingspondylitis,ASAS)20和BASDAI50反应率。结果对照组、治疗组ASAS20反应率分别为25%、75%,BASDAI50反应率分别为10%、70%,两组ASAS20和BASDAI50反应率比较,差异存在显著性(P<0.05,或P<0.01)。治疗后,治疗组患者的生活质量、VAS评分、症状体征评分、BASDAI、BASFI、BAS-G、BAS-MI及血浆急性时相反应物水平显著改善,且显著优于对照组(P<0.05,或P<0.01)。结论 XFC临床疗效优于柳氮磺胺吡啶,XFC可改善临床症状及相关指标,提高AS患者生活质量。

Objective To observe therapeutic effects of Xinfeng Capsules （XFC）, a traditional Chinese medicine recipe for invigorating spleen qi, dissipating dampness and removing obstacles from collaterals, in treating ankylosing spondylitis （AS） and its effects on quality of life （QOL）, and to probe into the mecha- nism of action. Methods Sixty AS patients were randomly divided into treatment group and control group according to random digits table. Forty patients in treatment group were treated with XFC, and 20 patients in control group with salazosulfapyridine （SASP）. Before and after treatment, scores of main symptoms and signs, QOL, and levels of serum acute phase reactants, erythrosedimentation （ESR） and C-reactive protein （CRP）, were observed in patients of both groups; disease conditions were evaluated using Bath ankylosing spondylitis metrological index （BASMI）, Bath ankylo：dHg spondylitis functional index （BASFI）, Bath ankylosing spondylitis activity index （BASDAI）, and Bath ankylosing spondylitis global index （BAS G）, respectively. QOL was evaluated using Brief Version of WHO Quality of Life （WHO- QOL-BRIEF）, pain using visual analog scoring （VAS）, anxiety status using self-rating anxiety scoring （SAS）, depression status using self-rating depression scoring （SDS）, and therapeutic effects using response rates of assessment in ankylosing spondylitis 20 （ASAS20） and BASDAIS0. Results Response rate ol ASAS20 in control group and treatment group was 25%, 75%, respectively; and response rate of BAS- DAI50 was 10%, 70%, respectively. There were significant differences in response rates of ASAS20 and BASDAIS0 between two groups （P〈0.05, or P〈0.01）. After treatment, QOL, scores of VAS, scores of main symptoms and signs, BASDAI, BASFI, BAS-G, BASMI, and serum levels of acute phase reactants were significantly ameliorated （P〈0.05, or P〈0.01） ; and treatment group was statistically superior to control group in ameliorating above-mentioned indicators （P〈0.05, or P〈0.01）. Conclusion Thera- peutic effects of XFC are superior to SASP in improving QOL, main symptoms and signs as well as related indicators in patients with AS.